{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:29:43Z","timestamp":1787869783472,"version":"build-2784847793"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T00:00:00Z","timestamp":1395705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ijpddr.2014.03.002","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T18:15:21Z","timestamp":1396721721000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine"],"prefix":"10.1016","volume":"4","author":[{"given":"Remington L.","family":"Nevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2014.03.002_b0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.clpt.2006.07.003","article-title":"MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine","volume":"80","author":"Aarnoudse","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0010","first-page":"60","article-title":"Antiplasmodial action and chemical constitution. Part II. Some simple synthetic analogues of quinine and cinchonine","volume":"125","author":"Ainley","year":"1938","journal-title":"Proc. R. Soc. London. Ser. B, Biol. Sci."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1172\/JCI101956","article-title":"Procedures used at Stateville penitentiary for the testing of potential antimalarial agents","volume":"27","author":"Alving","year":"1948","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(89)90795-7","article-title":"Selective neurotoxicity of clioquinol on the function of the posterior column nuclei","volume":"107","author":"Arasaki","year":"1989","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0025","first-page":"72","article-title":"CNS-toxic mefloquine (Lariam) still justified as a malaria medication?","volume":"44","author":"Arznei-Telegramm","year":"2013","journal-title":"Arznei-Telegramm"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0030","first-page":"84","article-title":"New warnings and contraindications for Lariam","volume":"44","author":"Arznei-Telegramm","year":"2013","journal-title":"Arznei-Telegramm"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0035","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijpddr.2012.01.004","article-title":"Chemotherapeutics challenges in developing effective treatments for the endemic malarias","volume":"2","author":"Baird","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.bjp.0705721","article-title":"Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice","volume":"141","author":"Barraud de Lagerie","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0045","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/cid\/cis976","article-title":"Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial","volume":"56","author":"Basra","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0050","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.2042-7158.1997.tb06047.x","article-title":"Stereoselective passage of mefloquine through the blood\u2013brain barrier in the rat","volume":"49","author":"Baudry","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0055","first-page":"760","article-title":"Pharmacology of 8-aminoquinolines and combinations of various synthetic antimalarials","volume":"23","author":"Benazet","year":"1963","journal-title":"M\u00e9decine Trop. Rev. du Corps sant\u00e9 Colon."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0060","unstructured":"Berliner, R.W., Blanchard, K.C., Butler, T.C., Clark, W.M., Marshall, E.K., Schmidt, L.H., Shannon, J.A., 1946. A Survey of Antimalarial Drugs, 1941\u20131945, vol. 2, Part 2: J.W. Edwards, Ann Arbor, Michigan; USA."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0065","first-page":"209","article-title":"Toxic encephalopathy induced by mefloquine: 3 case reports","volume":"17","author":"Bernard","year":"1989","journal-title":"Med. Armees"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0070","first-page":"9","article-title":"Mefloquine restrictions, anti-malarial drug safety and the new Italian recommendations for malaria prophylaxis","author":"Bisoffi","year":"2013","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0075","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(89)93029-8","article-title":"Acute psychosis following mefloquine prophylaxis","volume":"2","author":"Bj\u00f6rkman","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0080","article-title":"Malaria report #401: clinical toxicity of plasmocide (SN-3115, rhodoquine): review of the Russian and French literature","volume":"vol. 4","author":"Board for the Coordination of Malarial Studies","year":"1945"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0085","first-page":"798","article-title":"A synthetic remedy for malaria","volume":"2","author":"British Medical Journal","year":"1926","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0090","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, 2013. Core Safety Profile: Mefloquine, July 18, 2013, Bonn, Germany."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0095","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1176\/ajp.149.5.712a","article-title":"Acute depressive symptoms after mefloquine treatment","volume":"149","author":"Caillon","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0100","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/AAC.00874-07","article-title":"Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin","volume":"52","author":"Caridha","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0105","unstructured":"Centers for Disease Control and Prevention, 2013. FDA Revises Mefloquine Labeling; Drug Still Recommended <http:\/\/www.cdc.gov\/malaria\/features\/mefloquinelabeling.html>."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0110","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4269\/ajtmh.2011.11-0412","article-title":"Case report: peripheral polyneuropathy and mefloquine prophylaxis","volume":"85","author":"Chester","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2458-2-6","article-title":"Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?","volume":"2","author":"Croft","year":"2002","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0125","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/014107680710011411","article-title":"A lesson learnt: the rise and fall of Lariam and Halfan","volume":"100","author":"Croft","year":"2007","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JRS-2007-414","article-title":"Developing safe antimalaria drugs: key lessons from mefloquine and halofantrine","volume":"19","author":"Croft","year":"2007","journal-title":"Int. J. Risk Saf. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0135","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.psym.2011.11.001","article-title":"A naturalistic on-off-on trial of dextromethorphan\/quinidine for agitation associated with cerebellar injury","volume":"53","author":"Daly","year":"2012","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0140","first-page":"328","article-title":"Studies of the toxicity of plasmochine and rhodoquine","volume":"29","author":"Decourt","year":"1936","journal-title":"Bull. la Soci\u00e9t\u00e9 Pathol. Exot."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0145","doi-asserted-by":"crossref","first-page":"e79817","DOI":"10.1371\/journal.pone.0079817","article-title":"Addition of exogenous NAD(+) prevents mefloquine-induced neuroaxonal and hair cell degeneration through reduction of caspase-3-mediated apoptosis in cochlear organotypic cultures","volume":"8","author":"Ding","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0150","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.1002\/anie.201303931","article-title":"Concise synthesis and antimalarial activity of all four mefloquine stereoisomers using a highly enantioselective catalytic borylative alkene isomerization","volume":"52","author":"Ding","year":"2013","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2875-2-4","article-title":"Effect of sample size and P-value filtering techniques on the detection of transcriptional changes induced in rat neuroblastoma (NG108) cells by mefloquine","volume":"2","author":"Dow","year":"2003","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2875-2-14","article-title":"The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro","volume":"2","author":"Dow","year":"2003","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0165","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1128\/AAC.48.7.2624-2632.2004","article-title":"The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains","volume":"48","author":"Dow","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ygeno.2005.07.004","article-title":"Transcriptional profiling of mefloquine-induced disruption of calcium homeostasis in neurons in vitro","volume":"86","author":"Dow","year":"2005","journal-title":"Genomics"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0175","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/AAC.50.3.1045-1053.2006","article-title":"Mefloquine induces dose-related neurological effects in a rat model","volume":"50","author":"Dow","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1475-2875-10-150","article-title":"Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice","volume":"10","author":"Dow","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0185","unstructured":"Hoffmann-La Roche, F., 1989. Lariam Product Insert, United States, November 1989."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0190","unstructured":"Hoffmann-La Roche, F., 2013a. Lariam Summary of Product Characteristics, France, June, 2013."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0195","unstructured":"Hoffmann-La Roche, F., 2013b. Lariam Product Insert, Ireland, July 2013."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0200","unstructured":"Hoffmann-La Roche, F., 2014. Important safety related information: increased risk of eye disorders in connection with the use of Lariam\u00ae (mefloquine), Switzerland, January 29, 2014."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0205","first-page":"978","article-title":"Making good use of mefloquine","volume":"78","author":"F\u00e9lix","year":"1985","journal-title":"Bull. Soc. Pathol. Exot. Filiales"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0210","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.5694\/j.1326-5377.1973.tb129907.x","article-title":"Clioquinol encephalopathy","volume":"2","author":"Ferrier","year":"1973","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0215","first-page":"33","article-title":"The chemical approach to antimalarial compounds (I)","volume":"Vol. 2","author":"Findlay","year":"1950"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0220","first-page":"270","article-title":"The chemotherapeutic treatment of plasmodial infections","volume":"Vol. 2","author":"Findlay","year":"1950"},{"key":"10.1016\/j.ijpddr.2014.03.002_b9000","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0024-3205(00)00546-4","article-title":"Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes","volume":"66","author":"Fontaine","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpddr.2014.03.002_b9005","first-page":"473","article-title":"Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent","volume":"12","author":"Geng","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-2007-1017970","article-title":"Neuropsychiatric disturbances after malaria prophylaxis with mefloquine","volume":"21","author":"Grupp","year":"1994","journal-title":"Akt. Neurol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-25-1-103","article-title":"Plasmochin toxicity; analysis of 258 cases","volume":"25","author":"Hardgrove","year":"1946","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0235","first-page":"299","article-title":"A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand","volume":"61","author":"Harinasuta","year":"1983","journal-title":"Bull. World Health Org."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0240","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0140-6736(85)91670-8","article-title":"Trials of mefloquine in vivax and of mefloquine plus \u201cfansidar\u201d in falciparum malaria","volume":"1","author":"Harinasuta","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0245","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.neuro.2010.05.005","article-title":"Mefloquine induces oxidative stress and neurodegeneration in primary rat cortical neurons","volume":"31","author":"Hood","year":"2010","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0015-6264(81)90359-X","article-title":"Ultrastructural lesions of clioquinol toxicity in beagle dogs","volume":"19","author":"Hoover","year":"1981","journal-title":"Food Cosmet. Toxicol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0255","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.trstmh.2005.08.006","article-title":"Mefloquine toxicity presenting with polyneuropathy \u2013 a report of two cases in India","volume":"100","author":"Jha","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0379-0738(94)90376-X","article-title":"Mefloquine distribution in postmortem cases","volume":"68","author":"Jones","year":"1994","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0265","first-page":"175","article-title":"Transient global amnesia due to clioquinol","volume":"100","author":"Kaeser","year":"1984","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0270","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1086\/651682","article-title":"Efficacy and safety of mefloquine, artesunate, mefloquine\u2013artesunate, and praziquantel against Schistosoma haematobium: randomized exploratory open-label trial","volume":"50","author":"Keiser","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4269\/ajtmh.13-0013","article-title":"Adult malaria chemoprophylaxis prescribing patterns in the military health system from 2007 to 2011","volume":"89","author":"Kersgard","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0280","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sc.2010.68","article-title":"Cervical MRI of subacute myelo-optico-neuropathy","volume":"49","author":"Kimura","year":"2011","journal-title":"Spinal Cord"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0285","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1086\/504873","article-title":"Role of US military research programs in the development of US Food and Drug Administration\u2013approved antimalarial drugs","volume":"43","author":"Kitchen","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0290","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1021\/ol2010193","article-title":"Asymmetric total synthesis of the antimalarial drug (+)-mefloquine hydrochloride via chiral N-amino cyclic carbamate hydrazones","volume":"13","author":"Knight","year":"2011","journal-title":"Org. Lett."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7883\/yoken1952.24.195","article-title":"Subacute myelo-optico-neuropathy, a new neurological disease prevailing in Japan","volume":"24","author":"Kono","year":"1971","journal-title":"Jpn. J. Med. Sci. Biol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0300","first-page":"1","article-title":"Introductory review of subacute myeolo-optico-neuropathy (SMON) and its studies done by the SMON research commission","volume":"28","author":"Kono","year":"1975","journal-title":"Jpn. J. Med. Sci. Biol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0305","first-page":"776","article-title":"Transient disorders of memory after a malaria attack. Caused by mefloquine?","volume":"18","author":"Lapras","year":"1989","journal-title":"Press. M\u00e9dicale"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0310","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/cid\/cir839","article-title":"Global TravEpiNet: a national consortium of clinics providing care to international travelers\u2013analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009\u20132011","volume":"54","author":"LaRocque","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0315","first-page":"221","article-title":"Effects of mefloquine on Ca2+ uptake and release by dog brain microsomes","volume":"331","author":"Lee","year":"1996","journal-title":"Arch. Int. Pharmacodyn. th\u00e9rapie"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0320","unstructured":"Lobel, H.O., 1996. Adverse health events and malaria prophylaxis. Healthwise: a newsletter for peace corps medical officers worldwide 5, 1, 3\u20134."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0325","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1001\/jama.280.17.1483","article-title":"Drug overdoses with antimalarial agents: prescribing and dispensing errors","volume":"280","author":"Lobel","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0330","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4269\/ajtmh.1949.s1-29.341","article-title":"Pamaquine poisoning in man, with a clinicopathologic study of one case","volume":"29","author":"Loken","year":"1949","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0335","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/0002-9394(62)92202-X","article-title":"The selective effect of drugs upon nuclei of the oculogyric system","volume":"54","author":"Lyle","year":"1962","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0340","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11908-006-0033-5","article-title":"Malaria: diagnosis and treatment of falciparum malaria in travelers during and after travel","volume":"8","author":"Magill","year":"2006","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0345","unstructured":"Magill, A., Cersovsky, S., DeFraites, R., 2012. Special Considerations for US Military Deployments. 2012 CDC Yellow Book \u2013 Travelers\u2019 Health Chapter 8. <http:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2012\/chapter-8-advising-travelers-with-specific-needs\/special-considerations-for-us-military-deployments.htm>."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0350","first-page":"60","article-title":"Malaria, birds, and war","volume":"37","author":"Manwell","year":"1949","journal-title":"Am. Sci."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0355","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/jac\/dkr345","article-title":"Uptake of the antileishmania drug tafenoquine follows a sterol-dependent diffusion process in Leishmania","volume":"66","author":"Manzano","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0360","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/AAC.01545-10","article-title":"Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major","volume":"55","author":"Manzano","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0365","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.196.4288.415","article-title":"Malaria drugs: new ones are available, but little used","volume":"196","author":"Maugh","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0370","doi-asserted-by":"crossref","first-page":"579","DOI":"10.12659\/MSM.889033","article-title":"Mefloquine use, psychosis, and violence. a retinoid toxicity hypothesis","volume":"19","author":"Mawson","year":"2013","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0375","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jopan.2013.09.007","article-title":"Reply: possible confounding by mefloquine in the association of emergence delirium with PTSD and TBI among combat veterans","volume":"28","author":"McGuire","year":"2013","journal-title":"J. PeriAnesthesia Nurs."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0380","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neuro.2011.01.001","article-title":"Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase","volume":"32","author":"Milatovic","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0385","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.neuro.2011.05.002","article-title":"Response to Nevin, RL: mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning","volume":"32","author":"Milatovic","year":"2011","journal-title":"Neurotoxicology"},{"issue":"860","key":"10.1016\/j.ijpddr.2014.03.002_b0390","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.162.3860.1346","article-title":"Malaria and victory in Vietnam","volume":"162","author":"Modell","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0395","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0400","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1475-2875-8-188","article-title":"Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis","volume":"8","author":"Nevin","year":"2009","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0405","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.neuro.2011.05.003","article-title":"Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning","volume":"32","author":"Nevin","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0410","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tmaid.2012.03.006","article-title":"Limbic encephalopathy and central vestibulopathy caused by mefloquine: a case report","volume":"10","author":"Nevin","year":"2012","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0415","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4269\/ajtmh.2012.12-0277a","article-title":"Falling rates of malaria among U.S. military service members in Afghanistan substantiate findings of high compliance with daily chemoprophylaxis","volume":"87","author":"Nevin","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0420","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2011.12.016","article-title":"Investigating channel blockers for the treatment of multiple sclerosis: considerations with mefloquine and carbenoxolone","volume":"243","author":"Nevin","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0425","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jopan.2013.09.003","article-title":"Re: McGuire JM. The incidence of and risk factors for emergence delirium in U.S. Military Combat Veterans","volume":"28","author":"Nevin","year":"2013","journal-title":"J. PeriAnesthesia Nurs."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0430","first-page":"891","article-title":"Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine\u2013sulfadoxine\u2013pyrimethamine","volume":"65","author":"Nosten","year":"1987","journal-title":"Bull. World Health Org."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0435","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/jm00292a008","article-title":"Antimalarials. 7. Bis(trifluoromethyl)- -(2-piperidyl)-4-quinolinemethanols","volume":"14","author":"Ohnmacht","year":"1971","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0440","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/WNF.0b013e31823d78c4","article-title":"Dextromethorphan\/quinidine for chorea: an open-label assessment","volume":"35","author":"Ondo","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0445","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1086\/322694","article-title":"Atovaquone\u2013proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study","volume":"33","author":"Overbosch","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0450","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJM198911163212017","article-title":"Neurologic reactions after a therapeutic dose of mefloquine","volume":"321","author":"Patchen","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0455","first-page":"58","article-title":"Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria","volume":"37","author":"Pham","year":"1999","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0460","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0304-4165(00)00160-4","article-title":"Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT","volume":"1524","author":"Pham","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0465","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI101949","article-title":"The use of SN-10,275 in the prophylaxis and treatment of sporozoite-induced vivax malaria, Chesson strain","volume":"27","author":"Pullman","year":"1948","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s40278-013-6062-6","article-title":"US Army elite units instructed against mefloquine use","volume":"1471","author":"Reactions Weekly","year":"2013","journal-title":"React. Wkly."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0475","unstructured":"Reba, R.C., 1977. Report Number 1. Phase I Clinical Testing Antimalarial Drugs Annual Report. ADA044243, contract DAMD-17-75-C-5036. College Park, MD."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0480","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0035-9203(89)90253-8","article-title":"Tolerance of mefloquine alone and in combination with sulfadoxine\u2013pyrimethamine in the prophylaxis of malaria","volume":"83","author":"Reisinger","year":"1985","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0485","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0022-510X(82)90010-7","article-title":"Subacute myelo-optic neuropathy (SMON). First neuro-pathological report outside Japan","volume":"53","author":"Ricoy","year":"1982","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0490","first-page":"375","article-title":"Prophylactic activity of mefloquine hydrochloride (WR 142,490) in drug-resistant malaria","volume":"51","author":"Rieckmann","year":"1974","journal-title":"Bull. World Health Org."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0495","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-3156.1998.00163.x","article-title":"Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study","volume":"3","author":"R\u00f8nn","year":"1998","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0500","series-title":"Mefloquine Hydrochloride","author":"Roxanne Laboratories","year":"2013"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60241-0","article-title":"New experimental antimalarial drugs","volume":"16","author":"Rozman","year":"1979","journal-title":"Adv. Pharmacol. Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0510","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0140-6736(93)91107-W","article-title":"Mefloquine or doxycycline prophylaxis in US troops in Somalia","volume":"341","author":"S\u00e1nchez","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0515","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1708-8305.1996.tb00745.x","article-title":"Mefloquine, methodologies, and the media","volume":"3","author":"Schlagenhauf","year":"1996","journal-title":"J. Travel Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0520","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4269\/ajtmh.1997.56.235","article-title":"Tolerance of mefloquine by SwissAir trainee pilots","volume":"56","author":"Schlagenhauf","year":"1997","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0525","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1708-8305.1999.tb00843.x","article-title":"Mefloquine for malaria chemoprophylaxis 1992\u20131998: a review","volume":"6","author":"Schlagenhauf","year":"1999","journal-title":"J. Travel Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0530","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2310\/7060.2000.00069","article-title":"Neuropsychiatric events and travel: do antimalarials play a role?","volume":"7","author":"Schlagenhauf","year":"2000","journal-title":"J. Travel Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0535","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/1475-2875-9-357","article-title":"The position of mefloquine as a 21st century malaria chemoprophylaxis","volume":"9","author":"Schlagenhauf","year":"2010","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0540","first-page":"367","article-title":"Effects of pamaquine on the central nervous system","volume":"97","author":"Schmidt","year":"1947","journal-title":"Anat. Rec."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0545","first-page":"368","article-title":"Studies on the 8-aminoquinolines; the effects of plasmocid on the central nervous system","volume":"6","author":"Schmidt","year":"1947","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0550","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00005072-194810000-00002","article-title":"Neurotoxicity of the 8-aminoquinolines. I. Lesions in the central nervous system of the rhesus monkey induced by administration of plasmocid","volume":"7","author":"Schmidt","year":"1948","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0555","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cne.900910303","article-title":"Neurotoxicity of the 8-aminoquinolines. II. Reactions of various experimental animals to plasmocid","volume":"91","author":"Schmidt","year":"1949","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0560","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00005072-195107000-00001","article-title":"Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine, isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey","volume":"10","author":"Schmidt","year":"1951","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0565","first-page":"369","article-title":"Studies on the 8-aminoquinolines; the toxicities of pamaquine and plasmocid in different animal species","volume":"6","author":"Schmidt","year":"1947","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0570","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4269\/ajtmh.1955.4.208","article-title":"Review of investigations in malaria chemotherapy (U.S.A.) 1946\u20131954","volume":"4","author":"Schmidt","year":"1955","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0575","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.13.6.1011","article-title":"Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine)","volume":"13","author":"Schmidt","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0580","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.14.5.680","article-title":"Antimalarial activities of the 4-quinolinemethanols WR-184,806 and WR-226,253","volume":"14","author":"Schmidt","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0585","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/AAC.24.5.615","article-title":"Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys","volume":"24","author":"Schmidt","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0590","first-page":"17584","article-title":"Trapped in misbelief for almost 40 years: selective synthesis of the four stereoisomers of mefloquine","volume":"19","author":"Sch\u00fctzenmeister","year":"2013","journal-title":"Chemistry (Easton)."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0595","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1311439","article-title":"Expediting drug development\u2013the FDA\u2019s new \u201cbreakthrough therapy\u201d designation","volume":"369","author":"Sherman","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0600","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neulet.2012.03.040","article-title":"Suppression of autophagy exacerbates mefloquine-mediated cell death","volume":"515","author":"Shin","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0605","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7883\/yoken1952.24.217","article-title":"Neuropathology of subacute myelo-optico-neuropathy, \u201cSMON\u201d","volume":"24","author":"Shiraki","year":"1971","journal-title":"Jpn. J. Med. Sci. Biol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0610","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00005072-197307000-00009","article-title":"Plasmocid encephalopathy in the rhesus monkey: a study of selective vulnerability","volume":"32","author":"Sipe","year":"1973","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0615","first-page":"372","article-title":"Studies on the 8-aminoquinolines; on the relations between structure and pharmacological activities","volume":"6","author":"Smith","year":"1947","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0620","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S109285291300062X","article-title":"Mechanism of action of dextromethorphan\/quinidine: comparison with ketamine","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0625","first-page":"1011","article-title":"Aeromedical considerations of malaria prophylaxis with mefloquine hydrochloride","volume":"53","author":"Stockwell","year":"1982","journal-title":"Aviat. Space Environ. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0630","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jps.22249","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride","volume":"100","author":"Strauch","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0635","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.4269\/ajtmh.2010.10-0228","article-title":"A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons","volume":"83","author":"Tansley","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0640","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0140-6736(72)91014-8","article-title":"Strain differences in dogs for neurotoxicity of clioquinol","volume":"1","author":"Tateishi","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0645","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0140-6736(72)92392-6","article-title":"Neurotoxicity of clioquinol in laboratory animals","volume":"2","author":"Tateishi","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0650","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-200427010-00003","article-title":"Antimalarial drug toxicity: a review","volume":"27","author":"Taylor","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0655","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2307\/3903214","article-title":"Germany\u2019s new scientific researches reported. Synthetic rival to quinine","volume":"10","author":"The Science News-Letter","year":"1926","journal-title":"Sci. News-Letter"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0660","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7326\/0003-4819-70-1-150","article-title":"The army malaria research program","volume":"70","author":"Tigertt","year":"1969","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0665","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.1105787","article-title":"Mefloquine (WR 142,490) in the treatment of human malaria","volume":"190","author":"Trenholme","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0670","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0140-6736(71)92699-7","article-title":"Neurological syndrome associated with clioquinol","volume":"1","author":"Tsubaki","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0675","article-title":"Malaria report #290: results of study of plasmochin toxicity","volume":"Vol. 3","author":"U.S. Army Medical Department","year":"1943"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0680","unstructured":"U.S. Food and Drug Administration, 2012. FDA Adverse Events Reporting System (FAERS) \u2013 Potential Signals of Serious Risks\/New Safety Information Identified by the Adverse Event Reporting System (AERS) between April and June 2012 <http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm324020.htm>."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0685","unstructured":"Walter Reed Army Institute of Research, 2006. Neurotoxicity Associated with Mefloquine, an Anti-Malarial Drug: Small Business Technology Transfer (STTR) Solicitation Topic Number A06-T034 (Army) <http:\/\/www.dodsbir.net\/sitis\/archives_display_topic.asp?Bookmark=28959>."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0690","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1067\/moe.2001.115126","article-title":"Mefloquine-induced trigeminal sensory neuropathy","volume":"92","author":"Watt-Smith","year":"2001","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0695","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00117368","article-title":"The interrelationship of tropical disease and mental disorder: conceptual framework and literature review (Part I\u2013Malaria)","volume":"9","author":"Weiss","year":"1985","journal-title":"Cult. Med. Psychiatry"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0700","first-page":"87","article-title":"Plasmochin intoxication","volume":"82","author":"West","year":"1944","journal-title":"Bull. U.S. Army Med. Dep."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0705","unstructured":"Woodson, J., 2013. Assistant Secretary of Defense (Health Affairs) Memorandum. Subject: Notification for Healthcare Providers of Mefloquine Box Warning, August 12, 2013."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0710","first-page":"1147","article-title":"Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders","volume":"167","author":"Wooltorton","year":"2002","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0715","unstructured":"World Health Organization, 1984. Advances in malaria chemotherapy. Report of a WHO Scientific group. WHO Technical Report Series 711, Geneva, Switzerland."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0720","unstructured":"World Health Organization, 1989a. Central nervous system reactions related to the antimalarial drug, mefloquine. Report WHO\/MAL\/89\/1054 <http:\/\/whqlibdoc.who.int\/malaria\/WHO_MAL_89.1054.pdf>."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0725","first-page":"140","article-title":"Mefloquine: acute neurological reactions","volume":"3","author":"World Health Organization","year":"1989","journal-title":"WHO Drug Inf."},{"key":"10.1016\/j.ijpddr.2014.03.002_b0730","first-page":"131","article-title":"Subacute myelo-optico-neuropathy accompanied with vertigo","volume":"14","author":"Yamasaki","year":"1968","journal-title":"Otol. Fukuoka"},{"key":"10.1016\/j.ijpddr.2014.03.002_b0735","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12640-010-9221-z","article-title":"Mefloquine damage vestibular hair cells in organotypic cultures","volume":"20","author":"Yu","year":"2011","journal-title":"Neurotox. Res."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320714000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320714000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:43:08Z","timestamp":1761921788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320714000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2211320714000074"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2014.03.002","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2014.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}